LAS VEGAS — Patients with chronic pain may perceive improvements in sleep, pain, depression, and anxiety with the use of hemp-derived cannabidiol (CBD) oil, according to research presented at PAINWeek 2019, held September 3-7 in Las Vegas, Nevada.
A total of 648 patients utilizing Cannabidiol (CBD) oil containing <0.3% tetrahydrocannabinol were included in the study. A standard 11-point Likert scale was used to assess the perceived benefits of the Cannabidiol (CBD) product on chronic pain and associated conditions (ie, anxiety, insomnia, depression, and overall function), with 0 indicating no change and 10 indicating complete resolution.
Research participants reported using Cannabidiol (CBD) oil for a mean duration of 122±8 days. The mean improvements were 5.56 to 6.15 for insomnia, 5.36 to 5.94 for anxiety, 5.08 to 5.93 for depression, 4.81 to 6.48 for pain, and 5.06 to 5.50 for overall function. A 4-time daily dosing of Cannabidiol (CBD) oil was associated with statistically significant improvements in pain and related conditions compared with once-, twice-, or 3-times-daily dosing of the product.
Research limitations include its retrospective nature, the lack of placebo control, and the reliance on self-reports for assessment of outcomes.
“Physicians and other healthcare professionals can use these data to help decrease the use of prescription sleep aids, lower the opioid morphine equivalent dose, and decrease the use of benzodiazepines for anxiety,” lead research author Daniel C. Roth, DO, said Clinical Pain Advisor. “Overall, Cannabidiol (CBD) may be a clinically valuable tool in fighting the opioid epidemic, as it relates to controlled substances involved in accidental and illicit overdose deaths.”